TY - JOUR
T1 - Carborane based mesoporous nanoparticles as a potential agent for BNCT
AU - Wang, Yong
AU - Xu, Yanwen
AU - Yang, Jingying
AU - Qiu, Xiaoyan
AU - Li, Nan
AU - Zhu, Yuejin
AU - Yan, Lijuan
AU - Li, Weiping
AU - Huang, Xianjian
AU - Liang, Kaiyuan
AU - Guo, Rongjun
AU - Tan, Hui
AU - Yu, Haizhou Z.
N1 - Publisher Copyright:
© the Partner Organisations.
PY - 2021/3/21
Y1 - 2021/3/21
N2 - In view of the unique physical and chemical properties, boron rich carboranes have been preliminarily considered as candidates for boron neutron capture therapy (BNCT) in treatment of malignancies. However, before effectively implementing BNCT without damaging the normal cells, great challenges need to be addressed, such as sufficient accumulation of the boron-containing drug at the tumor site, high tumor-to-blood boron ratio and precise targeting. In this study, hydrophilic carborane-based nanoparticles with mesopores, DOX/CB@DMSNs(R), were synthesized. DMSNs(R) refers to dendritic mesoporous silica decorated with PEI-cRGD that could selectively target pancreatic tumor sites overexpressing integrin receptors. Doxorubicin (DOX) as both an anticancer drug and a fluorescence tracer has been well loaded into the mesopores. Such nanoparticles could suppress the leakage of boron into the bloodstream thanks to the covalent bonds, and exhibit outstanding boron loading (ca. 141.5 mg g-1) capacity and sufficient therapeutic dosage delivery (24.4 μg boron atoms g-1 tumor cells). Moreover, these nanoparticles could also selectively deliver boron and DOX to the tumor site. With such nanoparticles an admirable tumor-to-blood boron ratio of 27.1 and a high doxorubicin (DOX) loading (ca. 84.3 mg g-1) have been achieved. We envision that when carefully designed, DOX/CB@DMSNs(R) might serve as a BNCT agent, as well as a carrier of chemotherapy drugs, which could not only precisely target tumor cells, but also safely deliver sufficient drug dosage.
AB - In view of the unique physical and chemical properties, boron rich carboranes have been preliminarily considered as candidates for boron neutron capture therapy (BNCT) in treatment of malignancies. However, before effectively implementing BNCT without damaging the normal cells, great challenges need to be addressed, such as sufficient accumulation of the boron-containing drug at the tumor site, high tumor-to-blood boron ratio and precise targeting. In this study, hydrophilic carborane-based nanoparticles with mesopores, DOX/CB@DMSNs(R), were synthesized. DMSNs(R) refers to dendritic mesoporous silica decorated with PEI-cRGD that could selectively target pancreatic tumor sites overexpressing integrin receptors. Doxorubicin (DOX) as both an anticancer drug and a fluorescence tracer has been well loaded into the mesopores. Such nanoparticles could suppress the leakage of boron into the bloodstream thanks to the covalent bonds, and exhibit outstanding boron loading (ca. 141.5 mg g-1) capacity and sufficient therapeutic dosage delivery (24.4 μg boron atoms g-1 tumor cells). Moreover, these nanoparticles could also selectively deliver boron and DOX to the tumor site. With such nanoparticles an admirable tumor-to-blood boron ratio of 27.1 and a high doxorubicin (DOX) loading (ca. 84.3 mg g-1) have been achieved. We envision that when carefully designed, DOX/CB@DMSNs(R) might serve as a BNCT agent, as well as a carrier of chemotherapy drugs, which could not only precisely target tumor cells, but also safely deliver sufficient drug dosage.
UR - http://www.scopus.com/inward/record.url?scp=85103076129&partnerID=8YFLogxK
U2 - 10.1039/d0qm00867b
DO - 10.1039/d0qm00867b
M3 - 文章
AN - SCOPUS:85103076129
SN - 2052-1537
VL - 5
SP - 2771
EP - 2776
JO - Materials Chemistry Frontiers
JF - Materials Chemistry Frontiers
IS - 6
ER -